One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial
<h3>Context</h3>Adjuvant imatinib administered for 12 months after surgery has improved recurrence-free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared with placebo.<h3>Objective</h3>To investigate the role of imatinib administration du...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
28 March 2012
|
| In: |
The journal of the American Medical Association
Year: 2012, Jahrgang: 307, Heft: 12, Pages: 1265-1272 |
| ISSN: | 1538-3598 |
| DOI: | 10.1001/jama.2012.347 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1001/jama.2012.347 Verlag, Volltext: https://jamanetwork.com/journals/jama/fullarticle/1105116 
|
| Verfasserangaben: | Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Jörg T. Hartmann, Daniel Pink, Jochen Schütte, Giuliano Ramadori, Peter Hohenberger, Justus Duyster, Salah-Eddin Al-Batran, Marcus Schlemmer, Sebastian Bauer, Eva Wardelmann, Maarit Sarlomo-Rikala, Bengt Nilsson, Harri Sihto, Odd R. Monge, Petri Bono, Raija Kallio, Aki Vehtari, Mika Leinonen, Thor Alvegård, Peter Reichardt |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1581777493 | ||
| 003 | DE-627 | ||
| 005 | 20220815030333.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181011s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jama.2012.347 |2 doi | |
| 035 | |a (DE-627)1581777493 | ||
| 035 | |a (DE-576)511777493 | ||
| 035 | |a (DE-599)BSZ511777493 | ||
| 035 | |a (OCoLC)1341019855 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Joensuu, Heikki |e VerfasserIn |0 (DE-588)1121118747 |0 (DE-627)873981472 |0 (DE-576)480718318 |4 aut | |
| 245 | 1 | 0 | |a One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor |b a randomized trial |c Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Jörg T. Hartmann, Daniel Pink, Jochen Schütte, Giuliano Ramadori, Peter Hohenberger, Justus Duyster, Salah-Eddin Al-Batran, Marcus Schlemmer, Sebastian Bauer, Eva Wardelmann, Maarit Sarlomo-Rikala, Bengt Nilsson, Harri Sihto, Odd R. Monge, Petri Bono, Raija Kallio, Aki Vehtari, Mika Leinonen, Thor Alvegård, Peter Reichardt |
| 264 | 1 | |c 28 March 2012 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 11.10.2018 | ||
| 520 | |a <h3>Context</h3>Adjuvant imatinib administered for 12 months after surgery has improved recurrence-free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared with placebo.<h3>Objective</h3>To investigate the role of imatinib administration duration as adjuvant treatment of patients who have a high estimated risk for GIST recurrence after surgery.<h3>Design, Setting, and Patients</h3>Patients with KIT-positive GIST removed at surgery were entered between February 2004 and September 2008 to this randomized, open-label phase 3 study conducted in 24 hospitals in Finland, Germany, Norway, and Sweden. The risk of GIST recurrence was estimated using the modified National Institutes of Health Consensus Criteria.<h3>Intervention</h3>Imatinib, 400 mg per day, orally for either 12 months or 36 months, started within 12 weeks of surgery.<h3>Main Outcome Measures</h3>The primary end point was RFS; the secondary end points included overall survival and treatment safety.<h3>Results</h3>Two hundred patients were allocated to each group. The median follow-up time after randomization was 54 months in December 2010. Diagnosis of GIST was confirmed in 382 of 397 patients (96%) in the intention-to-treat population at a central pathology review. KIT or PDGFRA mutation was detected in 333 of 366 tumors (91%) available for testing. Patients assigned for 36 months of imatinib had longer RFS compared with those assigned for 12 months (hazard ratio [HR], 0.46; 95% CI, 0.32-0.65; P < .001; 5-year RFS, 65.6% vs 47.9%, respectively) and longer overall survival (HR, 0.45; 95% CI, 0.22-0.89; P = .02; 5-year survival, 92.0% vs 81.7%). Imatinib was generally well tolerated, but 12.6% and 25.8% of patients assigned to the 12- and 36-month groups, respectively, discontinued imatinib for a reason other than GIST recurrence.<h3>Conclusion</h3>Compared with 12 months of adjuvant imatinib, 36 months of imatinib improved RFS and overall survival of GIST patients with a high risk of GIST recurrence.<h3>Trial Registration</h3>clinicaltrials.gov Identifier: NCT00116935 | ||
| 700 | 1 | |a Sundby Hall, Kirsten |e VerfasserIn |0 (DE-588)1157321615 |0 (DE-627)1021179337 |0 (DE-576)502842091 |4 aut | |
| 700 | 1 | |a Hartmann, Jörg Thomas |e VerfasserIn |0 (DE-588)114847010 |0 (DE-627)606136843 |0 (DE-576)309276810 |4 aut | |
| 700 | 1 | |a Pinkston, Daniel A. |e VerfasserIn |0 (DE-588)1148442286 |0 (DE-627)1008714240 |0 (DE-576)496278517 |4 aut | |
| 700 | 1 | |a Schütte, Jochen |e VerfasserIn |0 (DE-588)1112272674 |0 (DE-627)866259791 |0 (DE-576)476490456 |4 aut | |
| 700 | 1 | |a Hohenberger, Peter |d 1953- |e VerfasserIn |0 (DE-588)1025311469 |0 (DE-627)72202875X |0 (DE-576)370195574 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |a American Medical Association |t The journal of the American Medical Association |d Chicago, Ill. : American Medical Association, 1883 |g 307(2012), 12, Seite 1265-1272 |h Online-Ressource |w (DE-627)316017000 |w (DE-600)2018410-4 |w (DE-576)091019974 |x 1538-3598 |7 nnas |
| 773 | 1 | 8 | |g volume:307 |g year:2012 |g number:12 |g pages:1265-1272 |g extent:8 |a One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor a randomized trial |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1001/jama.2012.347 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://jamanetwork.com/journals/jama/fullarticle/1105116 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181011 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 1025311469 |a Hohenberger, Peter |m 1025311469:Hohenberger, Peter |d 60000 |d 61800 |e 60000PH1025311469 |e 61800PH1025311469 |k 0/60000/ |k 1/60000/61800/ |p 8 | ||
| 999 | |a KXP-PPN1581777493 |e 3028438054 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"disp":"American Medical AssociationThe journal of the American Medical Association","type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 23.08.2019"],"corporate":[{"role":"aut","roleDisplay":"VerfasserIn","display":"American Medical Association"}],"language":["eng"],"recId":"316017000","physDesc":[{"extent":"Online-Ressource"}],"titleAlt":[{"title":"JAMA"}],"pubHistory":["1.1883 -"],"title":[{"subtitle":"JAMA","title":"The journal of the American Medical Association","title_sort":"journal of the American Medical Association"}],"origin":[{"dateIssuedKey":"1883","publisherPlace":"Chicago, Ill.","publisher":"American Medical Association","dateIssuedDisp":"1883-"}],"part":{"issue":"12","text":"307(2012), 12, Seite 1265-1272","pages":"1265-1272","volume":"307","extent":"8","year":"2012"},"id":{"eki":["316017000"],"issn":["1538-3598"],"zdb":["2018410-4"]}}],"origin":[{"dateIssuedDisp":"28 March 2012","dateIssuedKey":"2012"}],"id":{"doi":["10.1001/jama.2012.347"],"eki":["1581777493"]},"person":[{"given":"Heikki","family":"Joensuu","display":"Joensuu, Heikki","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Sundby Hall","given":"Kirsten","role":"aut","roleDisplay":"VerfasserIn","display":"Sundby Hall, Kirsten"},{"given":"Jörg Thomas","family":"Hartmann","role":"aut","roleDisplay":"VerfasserIn","display":"Hartmann, Jörg Thomas"},{"family":"Pinkston","given":"Daniel A.","display":"Pinkston, Daniel A.","role":"aut","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","role":"aut","display":"Schütte, Jochen","family":"Schütte","given":"Jochen"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Hohenberger, Peter","family":"Hohenberger","given":"Peter"}],"note":["Gesehen am 11.10.2018"],"recId":"1581777493","language":["eng"],"physDesc":[{"extent":"8 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Jörg T. Hartmann, Daniel Pink, Jochen Schütte, Giuliano Ramadori, Peter Hohenberger, Justus Duyster, Salah-Eddin Al-Batran, Marcus Schlemmer, Sebastian Bauer, Eva Wardelmann, Maarit Sarlomo-Rikala, Bengt Nilsson, Harri Sihto, Odd R. Monge, Petri Bono, Raija Kallio, Aki Vehtari, Mika Leinonen, Thor Alvegård, Peter Reichardt"]},"title":[{"title_sort":"One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor","title":"One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor","subtitle":"a randomized trial"}]} | ||
| SRT | |a JOENSUUHEIONEVSTHREE2820 | ||